| Assessment Status | Assessment Process Complete |
| HTA ID | 21011 |
| Drug | Olaparib |
| Brand | Lynparza® |
| Indication | Olaparib in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability. |
| Assessment Process | |
| Rapid review commissioned | 24/03/2021 |
| Rapid review completed | 28/04/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib in combination with bevacizumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/05/2021 |
| Pre-submission consultation with Applicant | 04/10/2021 |
| Full submission received from Applicant | 07/02/2022 |
| Preliminary review sent to Applicant | 02/09/2022 |
| NCPE assessment re-commenced | 11/11/2022 |
| Factual accuracy sent to applicant | 12/01/2023 |
| NCPE assessment re-commenced | 20/01/2023 |
| NCPE assessment completed | 27/01/2023 |
| NCPE assessment outcome | The NCPE recommends that olaparib in combination with bevacizumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
